Abstract
Background: Noonan syndrome (NS) is characterized by typical facial features, short stature, congenital heart defects and other comorbidities. Lymphedema and chylous pleural effusions are also common in NS, but protein-losing enteropathy (PLE) is rarely reported.
Case presentation: We present the case of a 19-year-old Chinese woman presenting with PLE. Small intestine biopsy showed obvious expansion of lymphatic vessels. The gene mutation results of the patient indicated a c.184T>G missense mutation (p.Tyr62Asp) in the PTPN11 gene (NM_002834.3).
Conclusion: NS accompanied by PLE is not common, but hypoproteinemia attributable to PLE may be more common in patients with NS than previously thought. It remains uncertain whether mutation of the PTPN11 gene is related to PLE, indicating that further research is needed.
Introduction
Noonan and Elimke first described a disease similar to Turner`s syndrome in 1963 in patients with a female or male phenotype, right-sided congenital heart diseases and a normal karyotype (Noonan, 1968). Henceforth, this type of disease with the same clinical manifestations is called Noonan syndrome (NS), which is characterized by typical facial features (ptosis and low-set posteriorly rotated ears), short stature, congenital heart defects, cryptorchidism in males, webbed neck, mild intellectual deficit, lymphatic dysplasia and other comorbidities (van der Burgt, 2007). The incidence of NS has been estimated to be between 1:1,000 and 1:2,500 live births (van der Burgt, 2007). NS is caused by germline pathogenic variant genes in the Ras/mitogen activated protein kinase (MAPK) signal transduction pathway (Sleutjes et al., 2022). At present, mutations of 10 genes, including protein tyrosine phosphatase non-receptor type 11 (PTPN11), son of sevenless homolog 1 (SOS1), Raf-1 proto-oncogene, serine/threonine kinase (RAF1), neuroblastoma RAS viral oncogene homolog (NRAS) and soc-2 suppressor of clear homolog (SHOC2), have been found (Tartaglia et al., 2007; Tartaglia et al., 2010; Kouz et al., 2016). Approximately 58% of NS cases are caused by missense mutations in the PTPN11 gene on chromosome 12 (Chinton et al., 2019). Different pathogenic mutations usually determine the manifestation of NS.
Lymphedema, mainly due to hypoplasia or dysplasia of lymphatic vessels, is also a clinical manifestation of NS. The estimated lifetime prevalence of lymphatic abnormalities in NS patients is 20%, including lymphedema, chylothorax and pulmonary lymphangiectasia (Tsang et al., 2000; Romano et al., 2010; Kouz et al., 2016; Biko et al., 2019). The most common lymphatic abnormality is lymphedema, which usually appears at birth and disappears in early childhood (Bloomfield et al., 1997; Ho et al., 2003). Lymphatic dysplasia can also be diagnosed by ultrasound in the prenatal phase based on increased neck translucency, cystic hygroma, pleural effusion and cervical lymphatic sac expansion, which all suggest the diagnosis of NS (Stuurman et al., 2019). However, lymphatic dysplasia may also occur in late childhood and adulthood (Romano et al., 2010). Severe lymphatic diseases mainly include chylothorax and protein-losing enteropathy (PLE) (Dori et al., 2020). Although lymphedema and chylous pleural effusions are common in NS (Lanning et al., 1978), the incidence of PLE is relatively low. PLE typically manifests as either syndromic or non-syndromic and is commonly associated with primary intestinal lymphangiectasia. Existing research has identified specific gene mutations that are linked to PLE (Fang et al., 2000; Van Balkom et al., 2002; Irrthum et al., 2003; Fotiou et al., 2015; van Rijn et al., 2018), including mutations in collagen and calcium binding EGF domains 1 (CCEB1), FAT tumor suppressor homolog 4 (FAT4), Piezo type mechanosensitive ion channel component 1 (PIEZO1), forkhead box C2 (FOXC2) and complement decay-accelerating factor (CD55). However, the association between PLE and specific gene mutations in NS has not been determined.
Here, we present the case of a 19-year-old Chinese woman presenting with severe edema and hypoproteinemia.
Case description
A 19-year-old woman was hospitalized due to progressive lower limb edema and oliguria for 2 weeks. Before admission, the patient’s laboratory results were as follows: albumin, 20.2 g/L (normal range of 40–55 g/L); calcium, 0.93 mmol/L (normal range of 2.11–2.52 mmol/L); potassium, 2.94 mmol/L (normal range of 3.5–5.3 mmol/L); blood routine hemoglobin, 97 g (normal range of 115–150 g); and urine samples showed positive urine protein. However, no definitive diagnosis was made. Only oral potassium chloride supplement was given, and the patient later presented to our hospital. The patient underwent surgical treatment for ptosis at age 11. She had menstruation at 12 years of age, and her menstrual cycle has been normal since then. There were no similar cases in the family, and no other family history required attention.
Physical examination showed the typical facial and skeletal abnormalities of NS as follows: height of 140 cm; weight of 48 kg, right ptosis, eye distance widened; low posterior hairline; low-set and posteriorly rotated ears; webbing of the neck; and high jaw bow. A grade 2–3 systolic blowing murmur was heard in the second intercostal space at the left edge of the sternum. Edema was generalized with severe pitting edema of both lower limbs.
Results
The laboratory study results can be found Table 1.
TABLE 1
| Examination items | Results | Normal range |
|---|---|---|
| white blood cell count | 10.48 × 109/L | 3.5–9.5 × 109/L |
| absolute lymphocyte count | 0.21 × 109/L | 1.1–3.2 × 109/L |
| hemoglobin | 88 g | 115–150 g |
| AST | 134 U/L | 13–55 U/L |
| ALT | 45 U/L | 7–40 U/L |
| total protein | 29.6 g/L | 65–85 g/L |
| albumin | 16 g/L | 40–55 g/L |
| corrected calcium | 1.22 mmol/L | 2.11–2.52 mmol/L |
| potassium | 3.2 mmol/L | 3.5–5.3 mmol/L |
| parathyroid hormone | 202 pg/mL | 15–68.3 pg/mL |
| synchronous 24 h urine calcium | 0.14 mmol/24 h | — |
| total 25-hydroxyvitamin D | ˂3.00 ng/mL | ˃30 ng/mL |
| 1,25-dihydroxyvitamin D3 | 36.47 pg/mL | 18–78 pg/mL |
| IgG | 2.47 g/L | 8.6–17.4 g/L |
| IgA | 0.36 g/L | 1.0–4.2 g/L |
| IgM | 0.59 g/L | 0.5–2.8 g/L |
The laboratory test results.
After calcium supplementation, the parathyroid hormone returned to normal (54.80 pg/mL), and pseudohypoparathyroidism was temporarily excluded. The arginine plus levodopa growth hormone stimulation test showed no growth hormone deficiency (fasting, 3.070 ng/mL; 0.5 h, 4.750 ng/mL; 1 h, 5.370 ng/mL; 1.5 h, 5.900; and 2.0 h, 13.530 ng/mL). The antibody related to celiac disease was normal. The bone marrow puncture results showed proliferative anemia, potential iron deficiency anemia, nucleated cell proliferation, granulocyte proliferation, normal erythron, normal megakaryocytes and no abnormal cells. The left wrist bone age radiograph provided the following bone ages: life age was 19 years and 5 months; R series bone age was 15 years and 10 months, which was 3 years and 7 months younger than the actual age of the patient; and C series bone age was 11 years and 0 months, which was 8 years and 5 months younger than the actual age of the patient. The cardiac ultrasound indicated congenital heart disease with an atrial septal defect (the defect opening of the left to right shunt in the center of the secondary foramen was approximately 0.62 cm wide and 0.56 cm wide, respectively). The plain computed tomography (CT) chest scan indicated a small amount of pleural effusion on both sides, and the heart border was slightly larger. The plain CT scan of the abdomen and pelvis indicated increased and blurred density of the peritoneal mesangium and omentum, and the surrounding fat was turbid, especially at the root of the mesangium. Scattered lymph nodes in the mesangium were observed, and the left anterior renal fascia was slightly thickened.
We next investigated the cause of hypoalbuminemia in the patient. The patient’s diet and liver function were normal, and the protein intake and synthesis were normal, suggesting that the hypoproteinemia may be caused by protein loss. The routine urine tests and urine protein were normal, indicating potential PLE. With the help of the digestive department, we completed a small bowel examination (fasting, bowel preparation until the stool becomes watery, tracheal intubation and general anesthesia are required due to the patient’s condition). Gastroduodenoscopy showed rough duodenal and jejunal segment mucosa and swollen and thickened villi with different sizes, and it also showed diffuse white granule-like changes and disorderly arranged villi. The intestinal fluid in the jejunal cavity was milky white. Lesions were present in the duodenal segment and the middle and upper segments of the jejunum. The small intestinal mucosa in the ileal segment was swollen with thickened and shortened villi, and a few white granules were present at the top. In the small intestinal mucosa, the villi were arranged in an orderly manner, and no obvious ulcers, proliferative foci or bleeding foci were found. These results suggested that the lymphatic vessels were dilated (Figure 1).
FIGURE 1
The diagnosis of Turner syndrome cannot be excluded based on the patient’s clinical signs. However, the chromosomal analysis results indicate 46, XX, which is inconsistent with Turner syndrome. To make a clear diagnosis, with the consent of the patient and herfamily, a whole exome test was performed. No mutation was detected in the patient’s mother and brother. The gene mutation results of the patient indicated a c.184T>G missense mutation (p.Tyr62Asp) in the PTPN11 gene (NM_002834.3) (Figure 2). Therefore, the patient was diagnosed with NS.
FIGURE 2
After discharge, the patient was treated with calcium carbonate D3 tablets (600 mg, twice a day)and ferrous succinate sustained-release tablets (one tablet, once a day). The patient was directed to consume a diet rich in medium-chain triglycerides (MCT), limit the intake of long-chain fatty acids, and increase their consumption of high-quality protein. Due to the advantages of MCT over long-chain fatty acids, including easier digestion, efficient energy supply, and reduced intestinal burden, they are suitable for patients with intestinal lymphatic dilation.
Discussion
NS is usually accompanied with lymphodysplasia (Nistal et al., 1984; Ogata et al., 2003; Tartaglia et al., 2010). Up to 20% of NS patients have lymphedema secondary to lymphodysplasia (Ho et al., 2003). A previous cross-sectional cohort study comprised of 35 patients with NS has reported that the prevalence of lymphedema is 49% and that the lymphedema is chronic and intermittent, mainly occurring in the limbs (Smpokou et al., 2012). Lymphedema associated with NS can occur at all ages, but it usually occurs at birth (Witt et al., 1987). Some features of NS, such as webbed neck, low hanging ears, low hairline and ptosis, may be related to intrauterine edema (Opitz, 1986), whereas intestinal lymphangiectasia usually occurs later (Herzog et al., 1976).
PLE is a rare disorder of gastrointestinal protein loss caused by a variety of diseases (Mizuochi et al., 2015). Intestinal lymphangiectasia is one of the causes of PLE (Mizuochi et al., 2015), and it is associated with intestinal loss of serum protein due to nonspecific expansion of intestinal mucosal lymphatic vessels, which is manifested as hypoproteinemia, hypogammaglobulinemia, peripheral blood edema and lymphopenia (Herzog et al., 1976). This change of intestinal lymphatic vessels may be caused by secondary reasons, such as poor development or obstruction of lymphatic vessels, which may be observed in various congenital and acquired diseases. NS may be accompanied by exaggerated intestinal lymphatic vessels and congenital heart disease, which may lead to refractory PLE.
A comprehensive literature search of the PubMed database from 1972 to 2022 using the “Noonan syndrome” and “PLE” search terms revealed only 11 reported cases (Table 2).
TABLE 2
| Cased | Sex | The onset of NS (yr) | The onset of PLE (yr) | Symptoms | Cardiac disorder | Transnodal lymphangiography | Treatments | Gene | Variant | Protein change | Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Matsumoto et al. (2015) | female | 17 | 17 | No | HCM | Absent thoracic duct; abdominal collateral lymphatics and bilateral iliac lymphangiectasia | Steroid therapy (1 mg/kg/d) Low-fat, protein-rich diet supplemented with medium chain triglycerides | Not provided | Relieved | ||
| Mizuochi et al. (2015) | female | 1.5 | 8 | Edema, Abdominal pain, diarrhea | ASD PVS | Not provided | Spironolactone (2.5 mg/kg/d) Furosemide (2.0 mg/kg/d) | Not provided | Relieved | ||
| Keberle et al. (2000) | male | 19 | 21 | Tibial edema Clubbing | Fallot`s tetralogy | Intestinal protein loss predominantly in the ileum | Low-fat, protein rich diet, medium chain triglycerides | Not provided | Relieved | ||
| Herzog et al. (1976) | female | 0.9 | 15 | Ankle swelling | ASD PVS | Hypoplasia of the lymphatics of the lower extremity and multiple ectatic lymph vessels in the mediastinal area and right supraclavicular area | Medium-chain triglyceride diet | Not provided | Relieved | ||
| Vallet et al. (1972) | Male | 0.3 | 6 | Diarrhea Anasarca, chylorrhea from the inguinal skin | PVS | Not provided | Medium-chain trigIycerides and a low-fat diet | Not provided | Died | ||
| Joyce et al. (2016) | male | 26 | 27 | genital swelling, bilateral lower limb lymphoedema | hypertrophic cardiomyopathy | Lymph reflflux/rerouting, bilateral popliteal LN, contrast in scrotum, multiple widened channels | low fat, high-protein diet | BRAF | c.770A>G | p.Gln257Arg | Not provided |
| Dori et al. (2020) | female | bleed | ventricular septal defect | unavailable | MEK inhibition | SOS1 | c.2536G>A | p.E846K | Relieved | ||
| Kleimeier et al. (2022) | male | 27 | 27 | unavailable | unavailable | unavailable | unavailable | SOS1 | c.1277A>C | p.Gln426Pro | Not provided |
| Wang et al. (2020) | female | 7 | 30 | Exrtimitis edema | Fllot`s tetralogy | Lymphangiectasis and bilateral widening of the venous angle in the mediastinum and small intestine | Low-fat, medium chain triglycerides | PTPN11 | c.A922G | p.N308D | Relieved |
| Hasegawa et al. (2009) | male | 6 | 13 | edema of his lower abdomen and hydrocele testis | ASD PVS | Protein loss from the small intestine | Albumin (2.5 g) Growth hormone | Not provided | Relieved | ||
| Our case | female | 19 | 19 | edema of both lower limbs | ASD | Low-fat, medium chain triglycerides | PTPN11 | c.184T>G | Tyr62Asp | Relieved |
Summary of all patients with NS-associated PLE identified in the literature (1972-2022).
A patient with NS combined with intestinal lymphangiectasia was first reported in 1972 (Vallet et al., 1972), and there have been relevant reports since then (Herzog et al., 1976). There is a certain relationship between NS and lymphangiectasia, but there are not many cases of NS with lymphangiectasia. The severity of intestinal lymphatic dilatation may be the cause of chronic malabsorption and growth retardation in patients (Vallet et al., 1972). Via endoscopy, lymphangiectasia shows white dilated villi in the duodenum (Kumar et al., 2021). The Noonan Syndrome Research Group of the University of London studied 112 patients with NS, and they did not detect lymphangiectasia in these patients (Shaw et al., 2007).
A Ras/MAPK pathway gene mutation is a candidate gene for NS (Razzaque et al., 2007; Roberts et al., 2007). The MAPK pathway is activated by vascular endothelial growth factor receptor 3 (VEGFR3), which is an important component of lymphangiogenesis (Tammela et al., 2005). Although the genotype-phenotype correlation of NS is not exact, the severity of lymphangiogenesis disorders may vary depending on gene mutations. In addition, the severity of lymphangiogenesis disorders may lead to different clinical symptoms of NS, including asymptomatic, only lymphedema or both lymphedema and PLE as well as early or late onset in time (Hasegawa et al., 2009). Some studies have found that patients with neuroblastoma have mutations in the PTPN11 gene and that these patients also have PLE (Obasaju et al., 2018). The PTPN11 gene is the most common pathogenic gene of NS, accounting for 30%–60% of NS cases. The PTPN11 gene is located on chromosome 12q24, and it contains 15 exons and 14 introns with a total length of 91,182 bp (Athota et al., 2020). The PTPN11 gene encodes the SHP2 protein tyrosine phosphatase, which contains three domains, namely, N-SH2, C-SH2, and PTP. The PTP domain contains phosphorylation active sites, and its activity is inhibited by the N-SH2 domain (Tajan et al., 2015). Approximately 50% of NS cases are caused by the missense variation of PTPN11 gene function acquisition. These variations are mainly distributed in the N-SH2 or PTP domain, rendering the inhibition of the N-SH2 domain ineffective. The PTP domain is also activated without phosphorylation via ligand binding, and upregulation of the Ras/MAPK signaling pathway leads to NS (Tajan et al., 2015). Eleven cases of PLE in NS have been recorded, including two cases associated with a germline PTPN11 mutation, involving the c.A922G and c.181G>A sites. The present case also involved a c.184T>G missense mutation of the PTPNT11 gene (p.Tyr62Asp), and PLE was the main clinical manifestation. It is unclear whether the mutation in the PTPN11 gene is more likely to cause PLE. The most common features of patients with NS due to PTPN11 mutations include heart defects (74%), low ear position (80%), low posterior hairline (68%), lower strabismus blepharoplasty (68%), cryptorchidism (94% of boys) and short stature (93%) (Zandrino et al., 2003; Yoshida et al., 2004; Sznajer et al., 2007). An infant with pulmonary lymphangiectasia (PL) was diagnosed with NS by genomic DNA sequence analysis after death because he had a G503R heterozygous mutation in the PTPN11 gene (Mathur et al., 2014). Pieper et al. diagnosed nine patients with NS and lymphatic abnormalities through dynamic contrast enhanced magnetic resonance (MR) lymphography, and among them, five patients had PTPN11 gene mutation (Pieper et al., 2022).
Japanese scholars have investigated the PTPN11 gene in 21 patients with NS; they identified 6 different heterozygous missense mutations in 7 cases (Asp61Gly, Tyr63Cys, Ala72Ser, Thr73Ile, Phe285Ser, and Asn308Asp) (Kosaki et al., 2002), but there was no report of PLE in these cases. It is currently believed that mutations in the PTPN11 gene may lead to relatively rare features of NS, such as sensory deafness and hemorrhagic diathesis (Kosaki et al., 2002). However, it remains unknown whether mutation of the PTPN11 gene is related to PLE, thereby warranting additional studies for confirmation.
In a previous case report for one patient with NS, an absent thoracic duct, abdominal collateral lymphatics and bilateral iliac lymphangiectasia were identified via lymphangiography (Matsumoto et al., 2015). It has also been reported that pedal lymphography and postlymphangiographic CT can be used to diagnose and study PLE (Keberle et al., 2000).
Dietary therapy, including low-fat diet and medium-chain triglyceride diet, is currently the cornerstone of lymphangiectasia therapy (Kumar et al., 2021). The medium-chain triglyceride diet also has a good effect on patients with NS complicated by exaggerated intestinal lymphatic vessels (Holt, 1964; Herzog et al., 1976). The medium-chain triglyceride diet has been shown to significantly improve hypoproteinemia, hypocalcemia and hypogammaglobulinemia. A previous study has reported that a patient with NS and congenital heart disease treated with standard doses of spironolactone and furosemide showed successful treatment of refractory PLE (Mizuochi et al., 2015), suggesting that diuretics effectively treat refractory PLE in patients with NS, but the specific physiological mechanism is unclear. Because the etiology of NS is the activation of the Ras/MAPK pathway, treatment with Ras/MAPK inhibitors may be feasible. At present, MEK inhibitors have been successfully used in patients with NS and severe lymphatic dysplasia (Li et al., 2019; Dori et al., 2020).
In terms of clinical presentation, consistent with our case, patients with protein-losing enteropathy (PLE) due to intestinal lymphangiectasia often exhibit hypoalbuminemia, particularly a significant decrease in albumin levels. They may also present with electrolyte disturbances such as severe hypocalcemia (Dori et al., 2020; Wang et al., 2020). When encountering cases of unexplained hypoalbuminemia in the absence of inadequate intake, non-protein synthesis disorders, or non-renal loss of protein, it is necessary to consider PLE as a potential diagnosis.
In conclusion, NS accompanied with PLE is not common, but asymptomatic hypoproteinemia attributable to PLE may be more common in patients with NS than previously thought. Therefore, when patients with NS have unexplained hypoproteinemia and hypoelectrolytes, they should be further evaluated for the presence of PLE, especially in patients with PTPN11 gene mutation.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.
Ethics statement
The studies involving humans were approved by Ethics Committee of Yunnan First People’s Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
Author contributions
YO read the literature and wrote the initial draft of the manuscript. J-CY and YZ collected the relevant information for the patient. J-MZ analyzed the data of genes. TH completed the enteroscopy. ZL read the literature. Y-KZ and ZL conceived and designed this study. Y-KZ revised the manuscript and guided the diagnosis and treatment of patients. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
NS, noonan syndrome; PLE, protein- loss enteropathy; MAPK, mitogen activated protein kinase; PTPN11, protein tyrosine phosphatase non-receptor type 11; SOS1, son of sevenless homolog 1; RAF1, raf-1 proto-oncogene, serine/threonine kinase; NRAS, neuroblastoma RAS viral oncogene homolog; SHOC2, soc-2 suppressor of clear homolog; CCEB1, collagen and calcium binding EGF domains 1; FAT4, FAT tumor suppressor homolog 4; PIEZO1, piezo type mechanosensitive ion channel component 1; FOXC2, forkhead box C2; CD55, complement decay-accelerating factor; VEGFR3, vascular endothelial growth factor receptor 3; PL, pulmonary lymphangiectasia; MCT, medium-chain triglycerides.
References
1
AthotaJ. P.BhatM.NampoothiriS.GowrishankarK.NarayanacharS. G.PuttamalleshV.et al (2020). Molecular and clinical studies in 107 Noonan syndrome affected individuals with PTPN11 mutations. BMC Med. Genet.21 (1), 50. 10.1186/s12881-020-0986-5
2
BikoD. M.ReisenB.OteroH. J.RavishankarC.VictoriaT.GlatzA. C.et al (2019). Imaging of central lymphatic abnormalities in Noonan syndrome. Pediatr. Radiol.49 (5), 586–592. 10.1007/s00247-018-04337-6
3
BloomfieldF. H.HaddenW.GunnT. R. (1997). Lymphatic dysplasia in a neonate with Noonan's syndrome. Pediatr. Radiol.27 (4), 321–323. 10.1007/s002470050139
4
ChintonJ.HuckstadtV.MorescoA.GravinaL. P.ObregonM. G. (2019). Clinical and molecular characterization of children with Noonan syndrome and other RASopathies in Argentina. Arch. Argent. Pediatr.117 (5), 330–337. 10.5546/aap.2019.eng.330
5
DoriY.SmithC.PintoE.SnyderK.MarchM. E.HakonarsonH.et al (2020). Severe lymphatic disorder resolved with MEK inhibition in a patient with noonan syndrome and SOS1 mutation. Pediatrics146 (6), e20200167. 10.1542/peds.2020-0167
6
FangJ.DagenaisS. L.EricksonR. P.ArltM. F.GlynnM. W.GorskiJ. L.et al (2000). Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am. J. Hum. Genet.67 (6), 1382–1388. 10.1086/316915
7
FotiouE.Martin-AlmedinaS.SimpsonM. A.LinS.GordonK.BriceG.et al (2015). Novel mutations in PIEZO1 cause an autosomal recessive generalized lymphatic dysplasia with non-immune hydrops fetalis. Nat. Commun.6, 8085. 10.1038/ncomms9085
8
HasegawaK.NagaokaY.MaruyamaH.AyaK.TanakaH.MorishimaT. (2009). Late-onset lymphedema and protein-losing enteropathy with noonan syndrome. Clin. Pediatr. Endocrinol.18 (3), 87–93. 10.1297/cpe.18.87
9
HerzogD. B.LoganR.KooistraJ. B. (1976). The Noonan syndrome with intestinal lymphangiectasia. J. Pediatr.88 (2), 270–272. 10.1016/s0022-3476(76)80998-5
10
HoW. L.WangJ. K.LiY. W. (2003). Radiological features of late-onset lymphoedema in Noonan's syndrome. Pediatr. Radiol.33 (3), 200–202. 10.1007/s00247-002-0768-6
11
HoltP. R. (1964). Dietary treatment of protein loss in intestinal lymphangiectasia. The effect of eliminating dietary long chain triglycerides on albumin metabolism in this condition. Pediatrics34, 629–635. 10.1542/peds.34.5.629
12
IrrthumA.DevriendtK.ChitayatD.MatthijsG.GladeC.SteijlenP. M.et al (2003). Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. Am. J. Hum. Genet.72 (6), 1470–1478. 10.1086/375614
13
JoyceS.GordonK.BriceG.OstergaardP.NagarajaR.ShortJ.et al (2016). The lymphatic phenotype in Noonan and Cardiofaciocutaneous syndrome. Eur J Hum Genet.24 (5), 690–696. 10.1038/ejhg.2015.175
14
KeberleM.MörkH.JenettM.HahnD.ScheurlenM. (2000). Computed tomography after lymphangiography in the diagnosis of intestinal lymphangiectasia with protein-losing enteropathy in Noonan's syndrome. Eur. Radiol.10 (10), 1591–1593. 10.1007/s003300000384
15
KleimeierL. E. R.van SchaikC.LeendersE.ItkinM.KleinW. M.DraaismaJ. M. T. (2022). Lymphatic phenotype of noonan syndrome: innovative diagnosis and possible implications for therapy. J. Clin. Med.11 (11), 3128. 10.3390/jcm11113128
16
KosakiK.SuzukiT.MuroyaK.HasegawaT.SatoS.MatsuoN.et al (2002). PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome. J. Clin. Endocrinol. Metab.87 (8), 3529–3533. 10.1210/jcem.87.8.8694
17
KouzK.LissewskiC.SprangerS.MitterD.RiessA.Lopez-GonzalezV.et al (2016). Genotype and phenotype in patients with Noonan syndrome and a RIT1 mutation. Genet. Med.18 (12), 1226–1234. 10.1038/gim.2016.32
18
KumarR.KumarT.AnandU.PriyadarshiR. N. (2021). Intestinal lymphangiectasia associated with refractory ascites in a cirrhosis patient. Cureus13 (1), e12567. 10.7759/cureus.12567
19
LanningP.SimiläS.SuramoI.PaavilainenT. (1978). Lymphatic abnormalities in Noonan's syndrome. Pediatr. Radiol.7 (2), 106–109. 10.1007/BF00975679
20
LiD.MarchM. E.Gutierrez-UzquizaA.KaoC.SeilerC.PintoE.et al (2019). ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor. Nat. Med.25 (7), 1116–1122. 10.1038/s41591-019-0479-2
21
MathurD.SomashekarS.NavarreteC.RodriguezM. M. (2014). Twin infant with lymphatic dysplasia diagnosed with Noonan syndrome by molecular genetic testing. Fetal Pediatr. Pathol.33 (4), 253–257. 10.3109/15513815.2014.904026
22
MatsumotoT.KudoT.EndoJ.HashidaK.TachibanaN.MurakoshiT.et al (2015). Transnodal lymphangiography and post-CT for protein-losing enteropathy in Noonan syndrome. Minim. Invasive Ther. Allied Technol.24 (4), 246–249. 10.3109/13645706.2014.996162
23
MizuochiT.SudaK.SekiY.YanagiT.YoshimotoH.KudoY.et al (2015). Successful diuretics treatment of protein-losing enteropathy in Noonan syndrome. Pediatr. Int.57 (2), e39–e41. 10.1111/ped.12603
24
NistalM.PaniaguaR.BravoM. P. (1984). Testicular lymphangiectasis in Noonan's syndrome. J. Urol.131 (4), 759–761. 10.1016/s0022-5347(17)50612-6
25
NoonanJ. A. (1968). Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am. J. Dis. Child.116 (4), 373–380. 10.1001/archpedi.1968.02100020377005
26
ObasajuP.BrondonJ.MirS.FordhamL. A.LeeS.BlattJ. (2018). Somatic PTPN11 mutation in a child with neuroblastoma and protein losing enteropathy. J. Pediatr. Hematol. Oncol.40 (4), 328–330. 10.1097/MPH.0000000000000903
27
OgataT.SatoS.HasegawaY.KosakiK. (2003). Lymphstasis in a boy with noonan syndrome: implication for the development of skeletal features. Endocr. J.50 (3), 319–324. 10.1507/endocrj.50.319
28
OpitzJ. M. (1986). On congenital lymphedema. Am. J. Med. Genet.24 (1), 127–129. 10.1002/ajmg.1320240115
29
PieperC. C.WagenpfeilJ.HenkelA.GeigerS.KösterT.HossK.et al (2022). MR lymphangiography of lymphatic abnormalities in children and adults with Noonan syndrome. Sci. Rep.12 (1), 11164. 10.1038/s41598-022-13806-w
30
RazzaqueM. A.NishizawaT.KomoikeY.YagiH.FurutaniM.AmoR.et al (2007). Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat. Genet.39 (8), 1013–1017. 10.1038/ng2078
31
RobertsA. E.ArakiT.SwansonK. D.MontgomeryK. T.SchiripoT. A.JoshiV. A.et al (2007). Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat. Genet.39 (1), 70–74. 10.1038/ng1926
32
RomanoA. A.AllansonJ. E.DahlgrenJ.GelbB. D.HallB.PierpontM. E.et al (2010). Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics126 (4), 746–759. 10.1542/peds.2009-3207
33
ShawA. C.KalidasK.CrosbyA. H.JefferyS.PattonM. A. (2007). The natural history of noonan syndrome: a long-term follow-up study. Arch. Dis. Child.92 (2), 128–132. 10.1136/adc.2006.104547
34
SleutjesJ.KleimeierL.LeendersE.KleinW.DraaismaJ. (2022). Lymphatic abnormalities in noonan syndrome spectrum disorders: A systematic review. Mol. Syndromol.13 (1), 1–11. 10.1159/000517605
35
SmpokouP.Tworog-DubeE.KucherlapatiR. S.RobertsA. E. (2012). Medical complications, clinical findings, and educational outcomes in adults with Noonan syndrome. Am. J. Med. Genet. A158a (12), 3106–3111. 10.1002/ajmg.a.35639
36
StuurmanK. E.JoostenM.van der BurgtI.EltingM.YntemaH. G.Meijers-HeijboerH.et al (2019). Prenatal ultrasound findings of rasopathies in a cohort of 424 fetuses: update on genetic testing in the NGS era. J. Med. Genet.56 (10), 654–661. 10.1136/jmedgenet-2018-105746
37
SznajerY.KerenB.BaumannC.PereiraS.AlbertiC.ElionJ.et al (2007). The spectrum of cardiac anomalies in Noonan syndrome as a result of mutations in the PTPN11 gene. Pediatrics119 (6), e1325–e1331. 10.1542/peds.2006-0211
38
TajanM.de Rocca SerraA.ValetP.EdouardT.YartA. (2015). SHP2 sails from physiology to pathology. Eur. J. Med. Genet.58 (10), 509–525. 10.1016/j.ejmg.2015.08.005
39
TammelaT.PetrovaT. V.AlitaloK. (2005). Molecular lymphangiogenesis: new players. Trends Cell Biol.15 (8), 434–441. 10.1016/j.tcb.2005.06.004
40
TartagliaM.PennacchioL. A.ZhaoC.YadavK. K.FodaleV.SarkozyA.et al (2007). Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat. Genet.39 (1), 75–79. 10.1038/ng1939
41
TartagliaM.ZampinoG.GelbB. D. (2010). Noonan syndrome: clinical aspects and molecular pathogenesis. Mol. Syndromol.1 (1), 2–26. 10.1159/000276766
42
TsangH. Y.CheungY. F.LeungM. P.ChauK. T. (2000). Cutaneous oozing of lymphatic fluid after interventional cardiac catheterization in a patient with Noonan syndrome. Catheter Cardiovasc Interv.51 (4), 441–443. 10.1002/1522-726x(200012)51:4<441::aid-ccd13>3.0.co;2-x
43
ValletH. L.HoltzappleP. G.EberleinW. R.YakovacW. C.MoshangT.BongiovanniA. M. (1972). Noonan syndrome with intestinal lymphangiectasis. A metabolic and anatomic study. J. Pediatr.80 (2), 269–274. 10.1016/s0022-3476(72)80589-4
44
Van BalkomI. D.AldersM.AllansonJ.BelliniC.FrankU.De JongG.et al (2002). Lymphedema-lymphangiectasia-mental retardation (hennekam) syndrome: a review. Am. J. Med. Genet.112 (4), 412–421. 10.1002/ajmg.10707
45
van der BurgtI. (2007). Noonan syndrome. Orphanet J. Rare Dis.2, 4. 10.1186/1750-1172-2-4
46
van RijnJ. M.ArdyR. C.KuloğluZ.HärterB.van Haaften-VisserD. Y.van der DoefH. P. J.et al (2018). Intestinal failure and aberrant lipid metabolism in patients with DGAT1 deficiency. Gastroenterology155 (1), 130–143. 10.1053/j.gastro.2018.03.040
47
WangN.ShiW.JiaoY. (2020). A PTPN11 mutation in a woman with Noonan syndrome and protein-losing enteropathy. BMC Gastroenterol.20 (1), 34. 10.1186/s12876-020-01187-1
48
WittD. R.HoymeH. E.ZonanaJ.ManchesterD. K.FrynsJ. P.StevensonJ. G.et al (1987). Lymphedema in noonan syndrome: clues to pathogenesis and prenatal diagnosis and review of the literature. Am. J. Med. Genet.27 (4), 841–856. 10.1002/ajmg.1320270412
49
YoshidaR.HasegawaT.HasegawaY.NagaiT.KinoshitaE.TanakaY.et al (2004). Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome. J. Clin. Endocrinol. Metab.89 (7), 3359–3364. 10.1210/jc.2003-032091
50
ZandrinoF.CuroneP.BenziL.MusanteF. (2003). Value of an early arteriographic acquisition for evaluating the splanchnic vessels as an adjunct to biphasic CT using a multislice scanner. Eur. Radiol.13 (5), 1072–1079. 10.1007/s00330-002-1566-0
Summary
Keywords
Noonan syndrome, lymphatic abnormalities, protein-losing enteropathy, PTPN11, intestinal lymphatic vessels
Citation
Ou Y, Yuan J-C, Zheng Y, Zhang J-M, He T, Liang Z and Zhou Y-K (2023) Case report: Noonan syndrome with protein-losing enteropathy. Front. Genet. 14:1237821. doi: 10.3389/fgene.2023.1237821
Received
10 June 2023
Accepted
12 September 2023
Published
27 September 2023
Volume
14 - 2023
Edited by
Thomas Smol, Université de Lille, France
Reviewed by
Anna Kłosowska, Medical University of Gdansk, Poland
Joseph M. Rutkowski, Texas A and M University, United States
Emilia Galperin, University of Kentucky, United States
Updates
Copyright
© 2023 Ou, Yuan, Zheng, Zhang, He, Liang and Zhou.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zhi Liang, zhiliang1973@sina.com; Yi-Kun Zhou, yikunzhou26@sina.com
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.